ATHA vs. ALGS, APLT, VTVT, GRI, CNTX, VHAQ, ME, FBRX, QNCX, and ONCY
Should you be buying Athira Pharma stock or one of its competitors? The main competitors of Athira Pharma include Aligos Therapeutics (ALGS), Applied Therapeutics (APLT), vTv Therapeutics (VTVT), GRI Bio (GRI), Context Therapeutics (CNTX), Viveon Health Acquisition (VHAQ), 23andMe (ME), Forte Biosciences (FBRX), Quince Therapeutics (QNCX), and Oncolytics Biotech (ONCY). These companies are all part of the "pharmaceutical products" industry.
Athira Pharma vs.
Athira Pharma (NASDAQ:ATHA) and Aligos Therapeutics (NASDAQ:ALGS) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, community ranking, risk, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.
Aligos Therapeutics received 7 more outperform votes than Athira Pharma when rated by MarketBeat users. Likewise, 65.85% of users gave Aligos Therapeutics an outperform vote while only 54.05% of users gave Athira Pharma an outperform vote.
Athira Pharma has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -1,283.19%. Aligos Therapeutics' return on equity of -114.34% beat Athira Pharma's return on equity.
Athira Pharma currently has a consensus price target of $13.83, suggesting a potential upside of 3,548.03%. Aligos Therapeutics has a consensus price target of $75.00, suggesting a potential upside of 420.83%. Given Athira Pharma's higher probable upside, analysts clearly believe Athira Pharma is more favorable than Aligos Therapeutics.
In the previous week, Athira Pharma and Athira Pharma both had 4 articles in the media. Athira Pharma's average media sentiment score of 0.98 beat Aligos Therapeutics' score of 0.56 indicating that Athira Pharma is being referred to more favorably in the media.
Aligos Therapeutics has higher revenue and earnings than Athira Pharma. Aligos Therapeutics is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks.
57.1% of Athira Pharma shares are held by institutional investors. Comparatively, 60.4% of Aligos Therapeutics shares are held by institutional investors. 19.8% of Athira Pharma shares are held by company insiders. Comparatively, 8.8% of Aligos Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Athira Pharma has a beta of 3, suggesting that its stock price is 200% more volatile than the S&P 500. Comparatively, Aligos Therapeutics has a beta of 2.52, suggesting that its stock price is 152% more volatile than the S&P 500.
Summary
Aligos Therapeutics beats Athira Pharma on 9 of the 16 factors compared between the two stocks.
Get Athira Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for ATHA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Athira Pharma Competitors List
Related Companies and Tools
This page (NASDAQ:ATHA) was last updated on 3/6/2025 by MarketBeat.com Staff
